1,730 Shares in Cencora, Inc. $COR Purchased by Burns Matteson Capital Management LLC

Burns Matteson Capital Management LLC acquired a new stake in Cencora, Inc. (NYSE:COR) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,730 shares of the company’s stock, valued at approximately $584,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in COR. Vanguard Group Inc. increased its stake in shares of Cencora by 4.1% in the third quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock worth $7,311,810,000 after purchasing an additional 916,506 shares in the last quarter. State Street Corp boosted its holdings in Cencora by 9.3% in the 3rd quarter. State Street Corp now owns 9,190,316 shares of the company’s stock worth $2,872,249,000 after buying an additional 782,911 shares during the period. JPMorgan Chase & Co. boosted its holdings in Cencora by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock worth $1,461,965,000 after buying an additional 821,098 shares during the period. Boston Partners grew its stake in Cencora by 2.0% in the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after buying an additional 89,506 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Cencora by 3.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,971,121 shares of the company’s stock valued at $1,241,094,000 after buying an additional 115,278 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.38% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Bank of America dropped their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. Wells Fargo & Company lifted their price target on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Finally, Evercore restated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Twelve research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $403.17.

Cencora Stock Up 1.3%

Shares of NYSE:COR opened at $313.88 on Wednesday. The firm has a fifty day moving average price of $350.42 and a two-hundred day moving average price of $341.25. The company has a market cap of $61.06 billion, a price-to-earnings ratio of 37.73, a PEG ratio of 1.44 and a beta of 0.68. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. Cencora, Inc. has a one year low of $267.40 and a one year high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping the consensus estimate of $4.04 by $0.04. The firm had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.73 earnings per share. Analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s dividend payout ratio (DPR) is presently 28.85%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.